Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13850893 | 0.92 | LMNA (0.46) | LMNAHPGDPLA2G2AMAPTTDP1 | |
| SCHEMBL12703877 | 0.91 | PLA2G2A (0.46) | LMNAHPGDPLA2G2AMAPTTDP1 | |
| SCHEMBL1593456 | 0.91 | LMNA (0.44) | LMNAHPGDPLA2G2AMAPTTDP1 | |
| SCHEMBL1593357 | 0.91 | LMNA (0.44) | LMNAHPGDPLA2G2AMAPTTDP1 | |
| SCHEMBL13851371 | 0.90 | LMNA (0.43) | LMNAHPGDPLA2G2AMAPTTDP1 | |
| SCHEMBL13850975 | 0.90 | LMNA (0.43) | LMNAHPGDPLA2G2AMAPTTDP1 | |
| SCHEMBL12703533 | 0.90 | LMNA (0.43) | LMNAHPGDPLA2G2AMAPTTDP1 | |
| SCHEMBL13850970 | 0.89 | MAPT (0.46) | LMNAHPGDPLA2G2AMAPTTDP1 | |
| SCHEMBL13850913 | 0.89 | LMNA (0.43) | LMNAHPGDPLA2G2AMAPTTDP1 | |
| SCHEMBL13850978 | 0.88 | EGLN2 (0.42) | LMNAHPGDPLA2G2AMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919623-B2 | Naphthyridine derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919623-B2 | Naphthyridine derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2009-05-07 | — | — | US | disclosed |
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2009-05-07 | — | — | US | disclosed |
| EP-2045242-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | Shionogi&Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7358249-B2 | Heterocyclic compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-7358249-B2 | Heterocyclic compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| EP-1714966-A1 | NAPHTHYLIDINE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | Shionogi Co., Ltd. (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | CYP3A7, CDK7, CYP2A7 | LMNA 1842/4885HPGD 3035/4885PLA2G2A 4460/4885 |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | PNP, CDKL1, ASNS | LMNA 1421/4885HPGD 3041/4885PLA2G2A 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.